These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38739215)

  • 61. Enthesitis in psoriatic arthritis.
    Sakkas LI; Alexiou I; Simopoulou T; Vlychou M
    Semin Arthritis Rheum; 2013 Dec; 43(3):325-34. PubMed ID: 23731532
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis.
    Mease PJ; Kavanaugh A; Ogdie A; Wells AF; Bergman M; Gladman DD; Richter S; Teng L; Jardon S; Smolen JS
    J Rheumatol; 2022 Jul; 49(7):694-699. PubMed ID: 35428720
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients.
    Orbai AM; McInnes IB; Coates LC; Husni ME; Gladman DD; Gossec L; Pricop L; Chambenoit O; Meng X; Mease PJ
    J Rheumatol; 2020 Jun; 47(6):854-864. PubMed ID: 31615919
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study.
    Mease PJ; Chohan S; Fructuoso FJG; Luggen ME; Rahman P; Raychaudhuri SP; Chou RC; Mendelsohn AM; Rozzo SJ; Gottlieb A
    Ann Rheum Dis; 2021 Sep; 80(9):1147-1157. PubMed ID: 33985942
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Results of one-year treat-to-target strategy in early psoriatic arthritis: data of an open-label REMARCA study.
    Korotaeva TV; Loginova EY; Getiya TS; Nasonov EL
    Ter Arkh; 2018 May; 90(5):22-29. PubMed ID: 30701886
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis.
    McInnes IB; Rahman P; Gottlieb AB; Hsia EC; Kollmeier AP; Chakravarty SD; Xu XL; Subramanian RA; Agarwal P; Sheng S; Jiang Y; Zhou B; Zhuang Y; van der Heijde D; Mease PJ
    Arthritis Rheumatol; 2021 Apr; 73(4):604-616. PubMed ID: 33043600
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Influence of Disease Manifestations on Health-related Quality of Life in Early Psoriatic Arthritis.
    Wervers K; Luime JJ; Tchetverikov I; Gerards AH; Kok MR; Appels CWY; van der Graaff WL; van Groenendael JHLM; Korswagen LA; Veris-van Dieren JJ; Hazes JMW; Vis M
    J Rheumatol; 2018 Nov; 45(11):1526-1531. PubMed ID: 29961685
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis.
    Gladman DD; Orbai AM; Gomez-Reino J; Chang-Douglass S; Leoncini E; Burton HE; Kanik KS; Romero AB; Cappelleri JC; Hsu MA
    Curr Ther Res Clin Exp; 2020; 93():100601. PubMed ID: 32983284
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Enthesitis in patients with psoriatic arthritis: A nationwide data from the Chinese Registry of Psoriatic Arthritis (CREPAR).
    Yang F; Lu C; Liu H; Dou L; Wang Y; Li H; Duan X; Wu L; Wang Y; Zhang X; Xu J; Su J; Xu D; Zhao J; Wu Q; Li M; Leng X; Zeng X
    Chin Med J (Engl); 2023 Apr; 136(8):951-958. PubMed ID: 37036901
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study.
    Coates LC; Helliwell PS
    J Rheumatol; 2016 Feb; 43(2):356-61. PubMed ID: 26669913
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: Findings from a real-world study in the United States and Europe.
    Walsh JA; Ogdie A; Michaud K; Peterson S; Holdsworth EA; Karyekar CS; Booth N; Middleton-Dalby C; Chakravarty SD; Dennis N; Gossec L
    Joint Bone Spine; 2023 May; 90(3):105534. PubMed ID: 36706947
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies.
    Nash P; Coates LC; Fleischmann R; Papp KA; Gomez-Reino JJ; Kanik KS; Wang C; Wu J; Menon S; Hendrikx T; Ports WC
    Rheumatol Ther; 2018 Dec; 5(2):567-582. PubMed ID: 30414064
    [TBL] [Abstract][Full Text] [Related]  

  • 73. GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis.
    Vieira-Sousa E; Alves P; Rodrigues AM; Teixeira F; Tavares-Costa J; Bernardo A; Pimenta S; Pimentel-Santos FM; Gomes JL; Aguiar R; Pinto P; Videira T; Catita C; Santos H; Borges J; Sequeira G; Ribeiro C; Teixeira L; Ávila-Ribeiro P; Martins FM; Canhão H; McInnes IB; Ribeiro RM; Fonseca JE
    Ann Rheum Dis; 2020 Apr; 79(4):490-498. PubMed ID: 32193187
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Canadian Adalimumab Postmarketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (COMPLETE-PsA): 12-month Results of Comparative Effectiveness of Adalimumab and nbDMARDs.
    Khraishi MM; Remple VP; Silverberg S; Stewart JC; Florica B; Bessette L
    J Rheumatol; 2022 May; 49(5):454-464. PubMed ID: 35033999
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Targeting extra-articular manifestations in PsA: a closer look at enthesitis and dactylitis.
    Siegel EL; Orbai AM; Ritchlin CT
    Curr Opin Rheumatol; 2015 Mar; 27(2):111-7. PubMed ID: 25603036
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Different biologics for biological-naïve patients with psoriatic arthritis: a systematic review and network meta-analysis.
    Lin J; Ren Y
    Front Pharmacol; 2024; 15():1279525. PubMed ID: 38545545
    [No Abstract]   [Full Text] [Related]  

  • 77. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
    Crowley JJ; Langley RG; Gordon KB; Pinter A; Ferris LK; Rubant S; Photowala H; Xue Z; Wu T; Zhan T; Beeck S; Shah M; Warren RB
    Dermatol Ther (Heidelb); 2022 Feb; 12(2):561-575. PubMed ID: 35050485
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies.
    Strober B; Menter A; Leonardi C; Gordon K; Lambert J; Puig L; Photowala H; Longcore M; Zhan T; Foley P
    J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2830-2838. PubMed ID: 32320088
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
    McInnes IB; Mease PJ; Ritchlin CT; Rahman P; Gottlieb AB; Kirkham B; Kajekar R; Delicha EM; Pricop L; Mpofu S
    Rheumatology (Oxford); 2017 Nov; 56(11):1993-2003. PubMed ID: 28968735
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension.
    Eder L; Gladman DD; Mease P; Pollock RA; Luna R; Aydin SZ; Ogdie A; Polachek A; Gruben D; Cadatal MJ; Kinch C; Strand V
    RMD Open; 2023 Mar; 9(1):. PubMed ID: 36958766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.